We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$891M
Cap. Flow
-$92.8M
Cap. Flow %
-0.89%
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
2 Financials 0.08%
3 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LLY icon
126
Eli Lilly
LLY
$1.09T
-112,000
Closed -$7.26M
PBYI icon
127
CALL
Puma Biotechnology
PBYI
$406M
-60,000
Closed -$14.3M
VTRS icon
128
Viatris
VTRS
$20.8B
-169,100
Closed -$7.69M
VIRX
129
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
-1,667
Closed -$2.5M
VIRX
130
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
-5,714
Closed -$8.57M
CSII
131
DELISTED
Cardiovascular Systems, Inc.
CSII
-170,000
Closed -$4.02M
GWPH
132
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
-221,000
Closed -$17.9M
FPRX
133
DELISTED
Five Prime Therapeutics, Inc.
FPRX
-1,075,400
Closed -$12.6M
SLXP
134
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
-200,000
Closed -$31.2M
CFN
135
DELISTED
CAREFUSION CORPORATION
CFN
-4,756,000
Closed -$215M
DRTX
136
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
-1,785,714
Closed -$22.6M
AMBI
137
DELISTED
Ambit Biosciences Corp
AMBI
-1,490,769
Closed -$23M
QGENF
138
DELISTED
QIAGEN NV
QGENF
-1,700,000
Closed -$38.7M

Similar funds

OrbiMed's Q4 2014 Portfolio in Review

As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
  • OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
  • OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
  • OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
  • OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
  • OrbiMed opened 14 new positions and closed 16 in Q4 2014.
  • OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.